Compare Arista Networks Inc (ANET) vs Sana Biotechnology Inc (SANA) Price & Performance

Arista Networks (ANET) trades at $209.29, up 9.28% in 24 hours, near its 52-week high. The stock exhibits bullish technical signals with strong moving average support. Fundamentally, revenue grew to $9.01B in 2025 with a 38.37% net margin, though valuation multiples like a 62.61 P/E are elevated. Recent quarters show consistent EPS beats, with Q2 2026 EPS of $1.02 exceeding expectations by 15%.

Outlook remains positive driven by AI data center demand, but risks include high valuation sensitivity and insider selling. Analyst consensus is strongly bullish with a $252.25 price target, implying 20% upside. Execution on AI networking growth and hyperscaler spending are key catalysts, while competition and margin pressure pose challenges.

SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.

The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.